🔴 Context Therapeutics Inc is trading 5.3% down today, extending a sell-off after Phase 1 data for ovarian cancer candidate CTIM-76

Context Therapeutics Inc is trading at $0.64 (5.3% down), extending a sharp sell-off triggered by interim Phase 1 data for its ovarian cancer candidate, CTIM-76.

• The stock plummeted 51.14% on June 15, 2026, following the initial clinical data release.
• Today's additional decline is attributed to continued negative momentum and profit-taking following the significant data-focused move.